Pfizer could have results from its late-stage coronavirus vaccine trial as early as October, CEO Albert Bourla said Thursday.
The pharmaceutical company has already enrolled 23,000 volunteers in the phase three trial that began in late July, Bourla said during a Q&A with the International Federation of Pharmaceutical Manufacturers & Associations, a trade group. It hopes to enroll at least 30,000 participants, he said.
“We expect by the end of October, we should have enough … to say whether the product works or not,” he said.
Pfizer’s potential vaccine is one of three backed by the U.S. that’s currently in late-stage testing. The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech. The companies’ experimental vaccine contains genetic material called messenger RNA, or mRNA. In July, the company released promising data from its early-stage trial.
The phase three trial is expected to include up to 30,000 participants between the ages of 18 and 85 across 120 sites globally, including 39 U.S. states, the company has said. If it is successful, they expect to submit it for final regulatory review as early as October. They plan to supply up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.
ENJOY FEEL GOOD, INSPIRING STORIES AND VIDEOS ?
Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.